Tempus AI has launched the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus’ multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development.

The next-generation of the Lens platform is built on over a decade of longitudinal real-world data and years of expertise translating that data into actionable evidence for biopharma. Lens combines one of the world's largest real-world multimodal datasets, high-performance AI computing, Tempus’ oncology foundation models, validated AI agents, and scientific workflows, all integrated into a single platform.

The platform was purpose-built to enable drug development teams to design better clinical trials, target patient subgroups faster, and generate critical evidence in a fraction of the time. Lens is commercially available today via lens.tempus.ai and is already utilised by a rapidly expanding user base, including 19 of the top 20 largest biopharma companies.

The multi-agent platform is designed to provide a seamless end-to-end experience through a suite of specialised tools. Lens co-scientist agents leverage deep contextual understanding of Tempus’ Real-World Data (RWD) model and available datasets, combined with oncology expertise, to generate insights and develop customised research plans. Researchers can submit complex biological hypotheses in plain language and receive targeted analysis plans that can be refined collaboratively with the AI agent. Once a plan is finalised, the platform can execute the analysis on demand, running code against Tempus’ extensive multimodal library of more than 8.5 million de-identified patient records to generate robust, code-backed results within minutes.

The platform also includes custom-validated AI agents tailored for specific real-world data applications, such as biomarker validation and clinical trial design support, helping optimise various stages of drug development and translational research workflows. To ensure transparency and reproducibility, results are delivered through interactive, shareable applications and reports, while users can access the underlying code, audit the analytical logic, or export projects to a private workspace for further technical development and validation.

Ryan Fukushima, CEO—Data and Apps, Tempus, said, "Drug development requires thousands of pivotal decisions between molecule and approval, and at its core, it is a navigation problem—most paths end in dead studies and wasted capital, which is why the industry needs a fundamentally different approach. Real-world multimodal data is complex, and turning it into decisions has historically required too much domain and data science expertise, resulting in weeks or months of manual analysis. The next generation of Lens consolidates this workflow into a single platform, with Tempus One serving as a co-scientist that does much of the heavy lifting. We've tuned every layer of the platform to empower biopharma teams to see the optimal development path clearly and make critical decisions faster than ever before."